jilicc apk
Moore's 33 lead Norfolk State past High Point 77-74
Prediction: These Will Be the Biggest (and Most Anticipated) Stock Splits for 2025Former President Jimmy Carter DiesBehind Donald Trump's Win, The Misplaced Optimism Of The White Liberal
Wait, did Trump endorse San Diego’s safe sleeping sites for homeless people?
The maritime industry is at a pivotal moment in its decarbonisation journey. Over the past decade, the sector has transitioned from focusing solely on air pollutants like sulphur oxides to adopting comprehensive strategies for reducing greenhouse gas emissions. This evolution presents both significant challenges and transformative opportunities for stakeholders across the globe. When the Energy Efficiency Design Index (EEDI) and Ship Energy Efficiency Management Plan (SEEMP) were introduced in 2013, they did more than establish new global benchmarks. They catalysed a shift in the industry’s approach to energy efficiency, laying the groundwork for operational performance measures like the Carbon Intensity Indicator (CII) and an increased focus on GHG emissions reduction for the sector using alternative fuels and innovative technologies. The introduction of regional regulations such as the EU’s maritime requirements, which could affect up to 30 per cent of the global fleet, have sharpened that focus. Dr Edmund Hughes, Director, Green Marine Associates Ltd Amid this focus, the critical role of the human element often remains underappreciated. Yet, it is clear that the success of maritime decarbonisation efforts depends not just on fuels, innovative energy systems and technological solutions, but also on the actions of shore staff and seafarers. These professionals are not merely operators of new systems – they are the key enablers of the industry’s sustainable future. Their decisions, from route planning to fuel management, determine whether advanced technologies achieve their full potential or fall short. This human-centric reality demands a fundamental shift in approach. Training must evolve from basic operational competencies to fostering a deep understanding of the systems they have to manage and energy efficiency principles. Shore teams need advanced skills to analyse complex performance data and optimise vessel operations, while seafarers require knowledge to align everyday practices with emissions goals. Most importantly, the industry must cultivate a culture where environmental protection becomes as integral to operations as safety awareness. Leadership plays a pivotal role in driving this transformation. Maritime executives must champion an organisational ethos that integrates environmental considerations into decision-making. This includes incentivising energy-efficient practices, fostering collaboration between ship and shore teams, and embedding environmental performance as a core metric of operational excellence. However, balancing regulatory compliance with operational realities remains a pressing challenge. For instance, fuel wasted by ships awaiting berth availability highlights inefficiencies that undermine sustainability efforts. The industry’s response, such as the International Maritime Organization’s (IMO) mandated Single Maritime Window for streamlined data exchange, exemplifies how digitalisation can address such issues. Similarly, Singapore’s upcoming requirement for electronic Bunker Delivery Notes underscores the shift toward digital solutions in emissions monitoring and compliance. Looking ahead, maritime GHG emissions pricing mechanisms will play a vital role in bridging the cost gap between traditional and green fuels. To be effective, these mechanisms must provide an enabling pathway, with funds allocated to incentivise green fuel adoption and mitigate investment risks for shipowners and fuel producers. The fundamental shift for shipping from Tank-to-Wake to Well-to-Wake compliance further underscores the need for advanced digital tools, including artificial intelligence, to navigate regulatory complexities. Front cover – Reducing Greenhouse Gas Emissions, A Guide to International Regulatory Compliance, Second Edition The path to maritime decarbonisation hinges on unprecedented collaboration. Sharing information across industry actors will enhance risk management and inform investment decisions, especially as the finalisation of IMO’s mid-term regulatory measures approaches. Resources like The International Chamber of Shipping’s ‘Reducing Greenhouse Gas Emissions: A Guide to International Regulatory Compliance, Second Edition’ offer invaluable guidance for navigating these challenges, providing stakeholders with actionable insights and a clear roadmap. The journey toward decarbonisation is not merely about compliance – it’s about building a sustainable, efficient future for shipping. Success will depend on the sector’s ability to adapt, innovate, and collaborate, transforming challenges into opportunities for growth and environmental stewardship. Source: By Dr Edmund Hughes, Director, Green Marine Associates Ltd, and contributor to ‘Reducing Greenhouse Gas Emissions: A Guide to International Regulatory Compliance, Second Edition’3 reasons to involve your kids in Small Business Saturday
https://arab.news/8nrhs JEDDAH: Saudi Arabia has officially launched the Jeddah Food Cluster, a major project aimed at transforming the city into a global business hub with an investment target of SR20 billion ($5.3 billion). Spanning 11 million sq. meters, the cluster is now recognized by Guinness World Records as the largest food park in the world by area. The development is expected to create over 43,000 jobs, driving both local and national economic growth. The opening ceremony, held on Nov. 24, was led by Prince Saud bin Mishal, deputy governor of Makkah, under the patronage of Prince Khaled Al-Faisal, governor of the Makkah region. It was attended by high-ranking officials, including Saudi Minister of Industry and Mineral Resources Bandar Alkhorayef. The inauguration of the cluster aligns with Saudi Arabia’s Vision 2030, which seeks to strengthen food security, achieve self-sufficiency, develop food value chains, and establish the Kingdom as a regional hub for attracting both domestic and international investment in the food sector. Located in Jeddah’s Second and Third Industrial Cities, the Jeddah Food Cluster is part of a larger industrial network in the Makkah region, which also includes industrial cities in Makkah and Taif. This region, which spans more than 50 million sq. meters, hosts over 2,000 industrial facilities specializing in sectors such as food production, pharmaceuticals, metals, and chemicals. The new food cluster is designed to enhance industrial productivity through cutting-edge infrastructure and strategic investments in key enablers. Currently, the cluster houses 124 operational factories with investments totaling SR4.4 billion. These factories are estimated to produce around 4 million tonnes of goods annually across 10 industrial sectors and provide jobs for over 7,000 workers. It also features 76 ready-to-use factories that comply with Saudi Food and Drug Authority standards. Additionally, the cluster has built a central laboratory to improve food quality and safety, as well as over 134,000 sq. meters of shared cold and dry storage facilities. By concentrating suppliers in one location, the cluster aims to create a sustainable, efficient supply chain. The economic impact of the Jeddah Food Cluster is expected to be substantial, with national exports projected to increase by SR8 billion. The development is also anticipated to create thousands of job opportunities, particularly in the industrial and logistics sectors, and contribute approximately SR7 billion to Saudi Arabia’s GDP over the next decade. This aligns with the broader objectives of Saudi Arabia’s National Industrial Strategy and the National Industrial Development and Logistics Program, which aim to foster economic diversification and sustainable growth. At the ceremony, MODON, the Saudi Authority for Industrial Cities and Technology Zones, announced that the Jeddah Food Cluster had achieved a significant milestone, receiving recognition from a global organization. Prince Saud also toured an exhibition showcasing the involvement of private companies and government entities in the food supply chain. This was followed by the presentation of the global recognition certificate. Several memorandums of understanding and agreements were signed during the event. These partnerships, which include collaborations with Umm Al-Qura University, the National Academy for Industry, and Halal Products Development Co., focus on developing specialized training programs, improving food safety, and promoting quality control within the food industry. Alkhorayef, in his speech, emphasized that the Jeddah Food Cluster represents more than just an industrial project—it is a key element in the Kingdom’s broader strategy for sustainable economic growth. “Through this cluster, we aim to leverage the ministry’s capabilities to serve Jeddah, the Kingdom’s economic hub, and a prime investment destination,” he said. He also highlighted the importance of connecting manufacturers, suppliers, and service providers to boost innovation and competitiveness, as well as to create new job opportunities, particularly for Saudi youth. On the sidelines of the event, a panel discussion titled “The Future of Global Food Supply Chain Resilience for Innovation and Sustainability” was held, featuring industry leaders such as Abdullah bin Nasser Al-Badr, CEO of Almarai, Betty Ka, director of supply chain and delivery at the UN World Food Program, and Fabio Maia de Oliveira, general investment director at JBS Saudi Arabia. The panel explored strategies for building resilient and sustainable global food supply chains. The launch of the Jeddah Food Cluster marks a significant step in Saudi Arabia’s ongoing efforts to diversify its economy and strengthen its position as a global leader in the food industry.
LANDOVER, Md. (AP) — The ball bounced through KaVonte Turpin's legs and stopped at the 1-yard line. He picked it up, made a spin move and was off to the races. Read this article for free: Already have an account? To continue reading, please subscribe: * LANDOVER, Md. (AP) — The ball bounced through KaVonte Turpin's legs and stopped at the 1-yard line. He picked it up, made a spin move and was off to the races. Read unlimited articles for free today: Already have an account? LANDOVER, Md. (AP) — The ball bounced through KaVonte Turpin’s legs and stopped at the 1-yard line. He picked it up, made a spin move and was off to the races. Turpin’s 99-yard kickoff return touchdown was the highlight of the Dallas Cowboys’ 34-26 win at Washington on Sunday that ended their losing streak at five. That came with just under three minutes left, and then Juanyeh Thomas returned an onside kick for a TD to provide a little happiness in the middle of a lost season. “Feels good to win,” coach Mike McCarthy said. “It’s been a minute.” Chauncey Golston ripping the ball out of Brian Robinson Jr.’s hands for what counted as an interception of Commanders rookie quarterback Jayden Daniels and Donovan Wilson forcing a fumble of John Bates earlier in the game helped put the Cowboys in position to make it a game, as did the play of Cooper Rush. Turpin’s monster return after initially muffing the retrieval had everyone buzzing. “He did that for timing,” McCarthy said. “That was part of the plan. He’s a special young man. Obviously a huge play for us.” Commanders safety Jeremy Reaves, the All-Pro special teams selection two seasons ago, was the first one down the field and blamed himself for not tackling Turpin when he had the chance. “I’ve made that play 100 times,” Reaves said. “I didn’t make it today, and it cost us the game.” Turpin’s spin move will likely be replayed over and over — and not stopped by many. Receiver CeeDee Lamb called it “his escape move” because Turpin has been showing it off in practice. “I know I can just get them going one way and then spin back the other way,” Turpin said. “That’s just one of my moves when I’m in trouble and I’ve got nowhere to go: something nobody ever seen before.” In a wacky finish that McCarthy likened to a game of Yahtzee, Thomas’ return was almost as unexpected. It came with 14 seconds left after Washington kicker Austin Seibert missed the extra point following Daniels’ 86-yard touchdown pass to Terry McLaurin to leave Dallas up 27-26. Winnipeg Jets Game Days On Winnipeg Jets game days, hockey writers Mike McIntyre and Ken Wiebe send news, notes and quotes from the morning skate, as well as injury updates and lineup decisions. Arrives a few hours prior to puck drop. “I kind of waited a second and I was like: ‘Should I try? Should I try?’” Thomas said. “I said, ‘I think I’m gonna score the ball,’ so just ran and I scored.” The Cowboys’ playoff odds are still incredibly long at 4-7, but with the New York Giants coming to town next for the traditional Thanksgiving Day game at Dallas, players are willing to dream after winning for the first time since Oct. 6. “Lot of games left,” said Rush, who threw two TD passes. “Pretty insane. ... I think both sides of the ball and special teams picked each other up all game. I think it was a full team effort. Finally picking each other up like we’re supposed to.” ___ AP NFL: https://apnews.com/hub/nfl Advertisement AdvertisementThe state should “never offer death as a service”, the Justice Secretary has said, in a strongly worded intervention over the assisted dying Bill ahead of a historic Commons vote next week. In a letter to constituents, Shabana Mahmood said she was “profoundly concerned” by the legislation, not just for religious reasons but because it could create a “slippery slope towards death on demand”. Ms Mahmood has previously made clear she would vote against the Bill alongside Health Secretary Wes Streeting , who faced a backlash after suggesting the changes would cost the NHS more. But her letter to voters, first reported by the Observer, goes further, stating: “Sadly, recent scandals – such as Hillsborough, infected blood and the Post Office Horizon – have reminded us that the state and those acting on its behalf are not always benign. “I have always held the view that, for this reason, the state should serve a clear role. It should protect and preserve life, not take it away. The state should never offer death as a service.” She said “the greatest risk of all is the pressure the elderly, vulnerable, sick or disabled may place upon themselves”. The intervention appears to be at odds with guidance set out by Cabinet Secretary Simon Case last month that ministers should remain neutral on the issue and avoid taking part in public debate. Prime Minister Sir Keir Starmer has declined to say whether he will back the Bill, arguing that he does not want to pressure MPs. Members will be given a free vote to act according to their personal beliefs, rather than in line with party policy. But prominent figures including former prime minister Gordon Brown have voiced opposition to the legislation. Ms Mahmood, Mr Streeting and Education Secretary Bridget Phillipson have said they will vote against the Bill while care minister Stephen Kinnock said he supports it. Proponents argue existing legislation fails to respect patient autonomy and discriminates financially between those who can afford to travel abroad to end their lives within the law and those who cannot. Leading barristers including former director of public prosecutions Sir Max Hill KC have spoken in favour of the Bill, saying it would offer better safeguards than the current system through a process involving two doctors and a judge. Labour MP Kim Leadbeater has described her Bill as the most “robust” in the world, with “three layers of scrutiny” in the form of a sign-off by two doctors and a High Court judge. It would also make coercion an offence with a possible punishment of 14 years in jail. The Bill, which covers England and Wales, states only terminally ill adults with under six months left to live and a settled wish to die would be eligible.
Stephanie Armour, Julie Rovner | (TNS) KFF Health News Many of President-elect Donald Trump’s candidates for federal health agencies have promoted policies and goals that put them at odds with one another or with Trump’s choice to run the Department of Health and Human Services, Robert F. Kennedy Jr., setting the stage for internal friction over public health initiatives. Related Articles National Politics | Biden will decide on US Steel acquisition after influential panel fails to reach consensus National Politics | Biden vetoes once-bipartisan effort to add 66 federal judgeships, citing ‘hurried’ House action National Politics | An analyst looks ahead to how the US economy might fare under Trump National Politics | Trump again calls to buy Greenland after eyeing Canada and the Panama Canal National Politics | House Ethics Committee accuses Gaetz of ‘regularly’ paying for sex, including with 17-year-old girl The picks hold different views on matters such as limits on abortion, the safety of childhood vaccines, the COVID-19 response, and the use of weight-loss medications. The divide pits Trump picks who adhere to more traditional and orthodox science, such as the long-held, scientifically supported findings that vaccines are safe, against often unsubstantiated views advanced by Kennedy and other selections who have claimed vaccines are linked with autism. The Trump transition team and the designated nominees mentioned in this article did not respond to requests for comment. It’s a potential “team of opponents” at the government’s health agencies, said Michael Cannon, director of health policy studies at the Cato Institute, a libertarian policy organization. Kennedy, he said, is known for rejecting opposing views when confronted with science. “The heads of the FDA and NIH will be spending all their time explaining to their boss what a confidence interval is,” Cannon said, referring to a statistical term used in medical studies. Those whose views prevail will have significant power in shaping policy, from who is appointed to sit on federal vaccine advisory committees to federal authorization for COVID vaccines to restrictions on abortion medications. If confirmed as HHS secretary, Kennedy is expected to set much of the agenda. “If President Trump’s nomination of RFK Jr. to be secretary is confirmed, if you don’t subscribe to his views, it will be very hard to rise in that department,” said Amesh Adalja, an infectious disease specialist and senior scholar at the Johns Hopkins Center for Health Security. “They will need to suppress their views to fit with RFK Jr’s. In this administration, and any administration, independent public disagreement isn’t welcome.” Kennedy is chair of Children’s Health Defense , an anti-vaccine nonprofit. He has vowed to curb the country’s appetite for ultra-processed food and its incidence of chronic disease. He helped select Trump’s choices to lead the Centers for Disease Control and Prevention, the Food and Drug Administration, and the National Institutes of Health. If confirmed, he would lead them from the helm of HHS, with its more than $1.7 trillion budget. Clashes are likely. Kennedy has supported access to abortion until a fetus is viable. That puts him at odds with Dave Weldon, the former Florida congressman whom Trump has chosen to run the CDC. Weldon, a physician, is an abortion opponent who wrote one of the major laws allowing health professionals to opt out of participating in the procedure. Weldon would head an agency that’s been in the crosshairs of conservatives since the COVID pandemic began. He has touted his “100% pro-life voting record” on his campaign website. (He unsuccessfully ran earlier this year for a seat in Florida’s House of Representatives.) Trump has said he would leave decisions about abortion to the states, but the CDC under Weldon could, for example, fund studies on abortion risks. The agency could require states to provide information about abortions performed within their borders to the federal government or risk the loss of federal funds. Weldon, like Kennedy, has questioned the safety of vaccines and has said he believes they can cause autism. That’s at odds with the views of Marty Makary, a Johns Hopkins surgeon whom Trump plans to nominate for FDA commissioner. The British American said on the “Brian Kilmeade Show” on Fox News Radio that vaccines “save lives,” although he added that it’s good to question the U.S. vaccine schedule for children. The American Academy of Pediatricians encourages parents and their children’s doctors to stick to the recommended schedule of childhood vaccines. “Nonstandard schedules that spread out vaccines or start when a child is older put entire communities at risk of serious illnesses, including infants and young children,” the group says in guidance for its members. Jay Bhattacharya, a doctor and economist who is Trump’s selection to lead NIH, has also supported vaccines. Kennedy has said on NPR that federal authorities under his leadership wouldn’t “take vaccines away from anybody.” But the FDA oversees approval of vaccines, and, under his leadership, the agency could put vaccine skeptics on advisory panels or could make changes to a program that largely protects vaccine makers from consumer injury lawsuits. “I do believe that autism does come from vaccines,” Kennedy said in 2023 on Fox News . Many scientific studies have discredited the claim that vaccines cause autism. Ashish Jha, a doctor who served as the White House COVID response coordinator from 2022 to 2023, noted that Bhattacharya and Makary have had long and distinguished careers in medicine and research and would bring decades of experience to these top jobs. But, he said, it “is going to be a lot more difficult than they think” to stand up for their views in the new administration. It’s hard “to do things that displease your boss, and if [Kennedy] gets confirmed, he will be their boss,” Jha said. “They have their work cut out for them if they’re going to stand up for their opinions on science. If they don’t, it will just demoralize the staff.” Most of Trump’s picks share the view that federal health agencies bungled the pandemic response, a stance that resonated with many of the president-elect’s voters and supporters — even though Trump led that response until Joe Biden took office in 2021. Kennedy said in a 2021 Louisiana House oversight meeting that the COVID vaccine was the “deadliest” ever made. He has cited no evidence to back the claim. Federal health officials say the vaccines have saved millions of lives around the globe and offer important protection against COVID. Protection lasts even though their effectiveness wanes over time. The vaccines’ effectiveness against infection stood at 52% after four weeks, according to a May study in The New England Journal of Medicine, and their effectiveness against hospitalization was about 67% after four weeks. The vaccines were produced through Operation Warp Speed, a public-private partnership Trump launched in his first term to fast-track the shots as well as other treatments. Makary criticized COVID vaccine guidance that called for giving young children the shots. He argued that, for many people, natural immunity from infections could substitute for the vaccine. Bhattacharya opposed measures used to curb the spread of COVID in 2020 and advised that everyone except the most vulnerable go about their lives as usual. The World Health Organization warned that such an approach would overwhelm hospitals. Mehmet Oz, Trump’s choice to head the Centers for Medicare & Medicaid Services, an agency within HHS, has said the vaccines were oversold. He promoted the use of the anti-malaria drug hydroxychloroquine as a treatment. The FDA in 2020 revoked emergency authorization of hydroxychloroquine for COVID, saying that it was unlikely to be effective against the virus and that the risk of dangerous side effects was too high. Janette Nesheiwat, meanwhile, a former Fox News contributor and Trump’s pick for surgeon general, has taken a different stance. The doctor described COVID vaccines as a gift from God in a Fox News opinion piece . Kennedy’s qualms about vaccines are likely to be a central issue early in the administration. He has said he wants federal health agencies to shift their focus from preparing for and combating infectious disease to addressing chronic disease. The shifting focus and questioning of vaccines concern some public health leaders amid the spread of the H5N1 bird flu virus among dairy cattle. There have been 60 human infections reported in the U.S. this year, all but two of them linked to exposure to cattle or poultry. “Early on, they’re going to have to have a discussion about vaccinating people and animals” against bird flu, said Georges C. Benjamin, executive director of the American Public Health Association. “We all bring opinions to the table. A department’s cohesive policy is driven by the secretary.” ©2024 KFF Health News. Distributed by Tribune Content Agency, LLC.
Viewers call out 'ridiculous' detail in Wheel of Fortune Australia rebootJimmy Carter, 39th President and Nobel Peace Prize Winner, Dies at 100
Insurers and healthcare middlemen are making it harder for everyday Americans, including many living with chronic diseases, to access the prescription drugs they need. Fortunately, Congress and President Joe Biden can address the problem by passing two bipartisan reforms during the current "lame duck" legislative session. For Democrats, this is a chance to build on the historic progress already made toward healthcare access and affordability for all Americans. At issue are middlemen known as "pharmacy benefit managers" -- or PBMs. PBMs act on behalf of insurance companies to negotiate with drug manufacturers and administer "formularies," or lists of which medications the insurer covers and what patients owe out of pocket. PBMs use their control over formularies to extract price concessions from drug companies in the form of rebates and discounts. Since drug makers want their products to be covered by insurers, they have a strong incentive to comply with PBMs' demands. In 2023 alone, the total value of rebates, discounts, and other payments to PBMs and insurers may have been as high as $334 billion. These savings could meaningfully reduce prescription drug costs for millions of patients. But in practice, many health plans simply keep rebates and discounts for themselves while continuing to charge patients based on the nominal "list price" of a drug, rather than the much lower "net price," which accounts for discounts and rebates. Consider a privately insured patient with diabetes. Let's assume the list price of the insulin she needs to survive is $1,000 per month, and her plan's coinsurance obligation is 25%. Let's also assume her insurer/PBM negotiates a 75% rebate off the insulin's price -- a 70-80% rebate is standard for many insulin brands. That'd leave the insurer/PBM paying a "net price" of $250 for the drug. But under current rules, the patient's health plan could still charge her based on the $1,000 per month list price of the insulin, meaning she'd owe $250 at the pharmacy counter. In this scenario, the sick patient would be covering 100% of what her health plan paid for the medicine. That isn't how insurance is supposed to work. This hypothetical example is no outlier. It's the reality for thousands of Americans with diabetes. One study found that people with diabetes could save $3.7 billion per year on their medications if insurers and PBMs passed rebates and discounts through to patients. A more fundamental issue is that in today's distorted market, PBM compensation is directly tied to how much medicines cost. The rebates, discounts, and fees PBMs collect are typically calculated as a percentage of a drug's list price. Since PBMs get to keep a portion of these payments for themselves, they naturally gravitate toward the most expensive drugs. While this setup works well for PBMs, it harms patients. Because PBMs make more money on expensive medicines, they're incentivized to select the costliest drugs for insurance plan coverage, even when cheaper alternatives exist. Over time, this inevitably leads to higher patient costs at the pharmacy counter. PBM practices hit the 129 million Americans living with heart disease, cancer, diabetes, and other chronic illnesses particularly hard. Around half of patients living with chronic diseases already skip doses or forgo treatment for cost reasons -- much higher than the overall rate of medication "nonadherence" among all adults. When patients don't take their medications as directed, whether it's because of cost or other reasons, manageable conditions can snowball into costly and life-threatening emergencies. By refusing to pass savings along to patients and pushing people toward the most expensive drugs, PBMs and insurers could be inadvertently making the problem of non-adherence worse. The good news is that Congress seems to be waking up to this reality. Two bipartisan reforms have been gathering momentum in recent months. One bill would delink PBM compensation from drug prices and the other would require health plans and PBMs to share rebates and discounts with patients. Both bills have already passed the Senate Finance Committee. For Democrats, this is a chance to demonstrate our commitment to equitable and affordable health care. PBM reform would help ensure our most vulnerable citizens, already reckoning with a cost of living crisis, aren't forced to choose between medication and other necessities. It's also an opportunity to build on Democrats' recent work to advance healthcare affordability through the Inflation Reduction Act and other legislation. But this isn't just a Democratic issue. A recent poll revealed that nearly two-thirds of voters would favor candidates who pass such legislation. PBM reform is that elusive combination of good policy and smart politics. PBM reform is a golden opportunity for Congress to deliver on a critical kitchen-table issue that impacts millions of Americans. Let's hope they take it. Kenneth E. Thorpe is the Robert W. Woodruff Professor of Health Policy at Emory University and the chairman of the Partnership to Fight Chronic Disease.
‘Living in a home that damages health the norm for far too many older people’
Certain CNN panellists seemed to think Scott Jennings was moonlighting as a comedian as he delved into President-elect Donald Trump ’s cabinet picks. Trump announced a new slate of nominees this week, adding allies from his former administration and Fox News contributors to his inner circle. When Jennings, however, suggested that Trump had chosen aides from a vast range of the political spectrum, he was met with poorly-suppressed laughter. ADVERTISEMENT “I think Trump is not getting enough credit here for building an ideologically diverse cabinet,” Jennings said on State of the Union on Sunday. The political strategist added: “I mean, you’ve got everybody from Russ Vought, who‘s very conservative, all the way over to the pick for Labor Secretary, is a supporter of the PRO Act.” At this point, both pro-GOP Shermichael Singleton and former Kamala Harris aide Jamal Simmons couldn’t stop their mouths from twitching. Jennings continued: “And somehow, Randi Weingarten is happy about it.” Host Dana Bash was the next to fall, letting out a laugh as Jennings carried on making his point. Not to be deterred, he said: “I mean, what he has done is - you know, which makes me squeamish, to be candid. And so, what he has done, though, is put together an ideologically diverse group of people to sit in a room and help run the government. “And that‘s kind of how he won! His coalition was kind of ideologically diverse that elected him.” Singleton then took over the conversation, and hinted that - whether ideologically diverse or not - Americans had to be ready to accept Trump’s cabinet. “When you win elections, you have a mandate whether you like it or not. The election is over, you guys,” he said. “The Heritage Foundation, AEI, the Hoover Institution have always supplied and recommended names for Republican administrations. This is nothing new. It will not be nothing new beyond Donald Trump. It‘s just a lot of democratic hoopla.” Karen Finney ended the discussion of Trump’s picks on an ominous note, suggesting that in his upcoming term we’d see a different presidency. “Look, I am for... I want the full Trump. I want it all out there. I want the country to see what Trump is all about. I want them to experience it,” she said.
Renard asks ‘average’ Saudi Arabia to ‘wake up’Stock market today: Wall Street slips to a rare back-to-back loss
NEW YORK (AP) — U.S. stock indexes drifted lower Tuesday in the runup to the highlight of the week for the market, the latest update on inflation that’s coming on Wednesday. The S&P 500 dipped 0.3%, a day after pulling back from its latest all-time high . They’re the first back-to-back losses for the index in nearly a month, as momentum slows following a big rally that has it on track for one of its best years of the millennium . Javascript is required for you to be able to read premium content. Please enable it in your browser settings. Success! An email has been sent to with a link to confirm list signup. Error! There was an error processing your request. Get the latest need-to-know information delivered to your inbox as it happens. Our flagship newsletter. Get our front page stories each morning as well as the latest updates each afternoon during the week + more in-depth weekend editions on Saturdays & Sundays.LEWISTON, N.Y. (AP) — Jaeden Marshall scored 21 points as Niagara beat Le Moyne 88-69 on Sunday. Marshall shot 5 for 8 (4 for 6 from 3-point range) and 7 of 8 from the free-throw line for the Purple Eagles (6-7). Justice Smith added 15 points while going 6 of 12 from the floor, including 1 for 3 from 3-point range, and 2 for 3 from the line and had five rebounds. Zion Russell shot 4 for 7, including 3 for 3 from beyond the arc to finish with 11 points. AJ Dancier finished with 17 points and four steals for the Dolphins (5-10). Le Moyne also got 11 points and 10 rebounds from Ocypher Owens. Dwayne Koroma had nine points and six rebounds. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .
None